Patent classifications
G01N2333/445
METHODS AND COMPOSITIONS FOR ANALYZING GLUCOSE-6-PHOSPHATE DEHYDROGENASE ACTIVITY IN BLOOD SAMPLES
Methods and compositions for the detection of glucose-6-phosphate dehydrogenase (G6PD) enzyme activity in blood samples are described. Some embodiments disclosed herein provide methods for detecting G6PD activity in undiluted or minimally diluted blood samples, including obtaining a blood sample, and detecting G6PD activity present in the undiluted or minimally diluted blood sample by epifluorescence. Also provided are methods for detecting G6PD activity and detecting a bloodborne microorganism as two parts of a single test.
MALARIA ANTIGEN SCREENING METHOD
The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.
Non-invasive method for detecting a deadly form of malaria
A non-invasive, continuous, and direct system for detecting the presence of malaria parasites that exploits the paramagnetic properties of hemozoin in red blood cells. An electromagnetic probe (EM probe) is comprised of a dual coaxial coil used to detect iron oxide particles by using sensitive lock-in amplification of detector voltage or phase shift.
NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE
Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
PLASMODIUM WITH HISTAMINE RELEASING FACTOR (HRF) DEFICIENCY FOR USE AS A VACCINE
A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 10.sup.3 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 10.sup.4 genetically modified live Plasmodium is administered to the primate. An immunogenic composition for administration to a primate, comprising a at least 10.sup.3 genetically modified live Plasmodium wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein; and at least one pharmaceutically acceptable excipient and/or support. In some embodiments the immunogenic composition comprises at least 10.sup.3 genetically a modified live Plasmodium.
A Spectral Imaging Platform For Infectious Disease Diagnosis
A low-cost and reconfigurable autonomous microscopy platform is provided capable of automated slide scanning and correlated brightfield and fluorescence imaging. Method of spectral imaging using the platform with applications including infectious disease diagnosis is also provided herein.
Molecular marker of plasmodium falciparum artemisinin resistance
K13-propeller polymorphism is a useful molecular marker for tracking the emergence and spread of ART-resistant P. falciparum. The invention encompasses methods, compositions, and kits for detecting and genotyping Plasmodium, for example, Plasmodium falciparum. The methods, compositions, and kits can be used to detect the presence or absence of a mutated K-13 propeller nucleic acid or protein in the sample.
Methods for diagnosing infectious diseases using adsorption media
The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.
SAMPLE ANALYSIS METHOD, SAMPLE ANALYZER, AND COMPUTER-READABLE STORAGE MEDIUM
A sample analysis method for analyzing a blood sample, a sample analyzer, and a computer-readable storage medium. Optical signals generated when particles in a test sample solution are illuminated by an excitation light when passing one by one through an optical detection area are acquired in one test, said sample solution being acquired when a blood sample is treated with a hemolytic agent, a first dye, and a second dye, the first dye being capable of dyeing white blood cells, the second dye being capable of dyeing infected red blood cells, the optical signals comprising a scattered light signal, a first fluorescent signal corresponding to the first dye, and a second fluorescent signal corresponding to the second dye; white blood cell optical information is acquired on the basis of the scattered light signal and of the first fluorescent signal; and red blood cell optical information is acquired on the basis of the scattered light signal and of the second fluorescent signal. Implemented by means of the present method is the simultaneous acquisition of the white blood cell optical information and the infected red blood cell optical information in a same detection channel or in a same test, thus reducing the volume of blood used in and costs for testing.
Anti-plasmodium falciparum HRP-II antibody
Provided is an anti-Plasmodium falciparum HRP-II antibody or an antigen-binding fragment thereof. The antibody comprises a heavy chain CDR1-3 shown in SEQ ID NO: 1-3 and a light chain CDR1-3 shown in SEQ ID NO: 4-6. Also provided are an application of the antibody and a method for preparing the antibody.